Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Human/Mouse |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-Myelin transcription factor 1 is suitable for use in Western Blot research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
Concentration: |
1 mg/mL |
Dilution Range: |
WB 1:500-2000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
MYT1 |
Gene ID: |
4661 |
Uniprot ID: |
MYT1_HUMAN |
Specificity: |
This antibody detects endogenous levels of MYT1 at Human, Mouse |
Immunogen: |
Synthesized peptide derived from human MYT1 |
Function | Binds to the promoter region of genes encoding proteolipid proteins of the central nervous system. May play a role in the development of neurons and oligodendroglia in the CNS. May regulate a critical transition point in oligodendrocyte lineage development by modulating oligodendrocyte progenitor proliferation relative to terminal differentiation and up-regulation of myelin gene transcription. |
Protein Name | Myelin Transcription Factor 1Myt1Myelin Transcription Factor IMytiPlpb1Proteolipid Protein-Binding Protein |
Cellular Localisation | Nucleus |
Alternative Antibody Names | Anti-Myelin Transcription Factor 1 antibodyAnti-Myt1 antibodyAnti-Myelin Transcription Factor I antibodyAnti-Myti antibodyAnti-Plpb1 antibodyAnti-Proteolipid Protein-Binding Protein antibodyAnti-MYT1 antibodyAnti-KIAA0835 antibodyAnti-KIAA1050 antibodyAnti-MTF1 antibodyAnti-MYTI antibodyAnti-PLPB1 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance